Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
6 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial.
Lancet Haematol. 2022 Oct;9(10):e733-e744. doi: 10.1016/S2352-3026(22)00208-3. Epub 2022 Aug 22.
Lancet Haematol. 2022.
PMID: 36007538
Clinical Trial.
Population Pharmacokinetics and Exposure-Response of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With Myelodysplastic Syndromes.
Chen N, Kassir N, Laadem A, Maxwell SE, Sriraman P, Giuseppi AC, Ritland S, Linde PG, Budda B, Reynolds JG, Zhou S, Palmisano M.
Chen N, et al. Among authors: giuseppi ac.
CPT Pharmacometrics Syst Pharmacol. 2020 Jul;9(7):395-404. doi: 10.1002/psp4.12521. Epub 2020 Jun 30.
CPT Pharmacometrics Syst Pharmacol. 2020.
PMID: 32602651
Free PMC article.
Item in Clipboard
Population Pharmacokinetics and Exposure-Response Relationship of Luspatercept, an Erythroid Maturation Agent, in Anemic Patients With β-Thalassemia.
Chen N, Kassir N, Laadem A, Giuseppi AC, Shetty J, Maxwell SE, Sriraman P, Ritland S, Linde PG, Budda B, Reynolds JG, Zhou S, Palmisano M.
Chen N, et al. Among authors: giuseppi ac.
J Clin Pharmacol. 2021 Jan;61(1):52-63. doi: 10.1002/jcph.1696. Epub 2020 Jul 21.
J Clin Pharmacol. 2021.
PMID: 32696522
Free PMC article.
Clinical Trial.
Item in Clipboard
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G.
Platzbecker U, et al. Among authors: giuseppi ac.
Lancet. 2023 Jul 29;402(10399):373-385. doi: 10.1016/S0140-6736(23)00874-7. Epub 2023 Jun 10.
Lancet. 2023.
PMID: 37311468
Clinical Trial.
Item in Clipboard
Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts.
Platzbecker U, Santini V, Komrokji RS, Zeidan AM, Garcia-Manero G, Buckstein R, Miteva D, Keeperman K, Holot N, Nadal JA, Lai Y, Vodala S, Rosettani B, Giuseppi AC, Yucel A, Fenaux P.
Platzbecker U, et al. Among authors: giuseppi ac.
Leukemia. 2023 Nov;37(11):2314-2318. doi: 10.1038/s41375-023-02031-7. Epub 2023 Sep 26.
Leukemia. 2023.
PMID: 37752285
Free PMC article.
No abstract available.
Item in Clipboard
Sotatercept Safety and Effects on Hemoglobin, Bone, and Vascular Calcification.
Coyne DW, Singh HN, Smith WT, Giuseppi AC, Connarn JN, Sherman ML, Dellanna F, Malluche HH, Hruska KA.
Coyne DW, et al. Among authors: giuseppi ac.
Kidney Int Rep. 2019 Aug 13;4(11):1585-1597. doi: 10.1016/j.ekir.2019.08.001. eCollection 2019 Nov.
Kidney Int Rep. 2019.
PMID: 31891000
Free PMC article.
Item in Clipboard
Cite
Cite